Investment in Cyclo Therapeutics, Inc. (Tables)

12 Months Ended

Jul. 31, 2023

Investment in Cyclo Therapeutics, Inc. [Abstract]

Schedule of Fair Value Method Investment

Summarized Fair Value (Level 1) Method Investment Details

	Ownership %			Aggregate Fair Value
	July 31, 2023			July 31, 2023
Cyclo		16	%	$	4,763,102

Schedule of Consolidated Financial Information

Summarized consolidated financial information of Cyclo, reported on a one month lag, is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenue	$	117,118		$	541,886		$	269,529		$	736,790
Loss from operations	$	(4,632,942	)	$	(3,456,024	)	$	(9,640,074	)	$	(6,390,481	)
Net loss	$	(4,636,455	)	$	(3,451,990	)	$	(9,643,540	)	$	(6,223,581	)